These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Managed care considerations. A new era of advanced prostate cancer management. Muller R Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721 [No Abstract] [Full Text] [Related]
3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Nabhan C N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391 [No Abstract] [Full Text] [Related]
5. Listening to Provenge--what a costly cancer treatment says about future Medicare policy. Chambers JD; Neumann PJ N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004 [No Abstract] [Full Text] [Related]
6. Is Provenge Angst a symbol or symptom of the times? Holcombe DG Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274 [No Abstract] [Full Text] [Related]
12. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer. Becze E ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750 [No Abstract] [Full Text] [Related]
14. Therapy: An immune one-two punch. Bourzac K Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788 [No Abstract] [Full Text] [Related]
15. Continuous improvement versus innovation: the case for sipuleucel-T. Tombal B Eur Urol; 2012 Apr; 61(4):648-9; discussion 650-1. PubMed ID: 22154024 [No Abstract] [Full Text] [Related]
16. Prostate cancer. Klemm J; Mehr SR Am J Manag Care; 2012 May; 18(3 Spec No.):SP119-21. PubMed ID: 22642277 [No Abstract] [Full Text] [Related]
17. How does sipuleucel-T alter our clinical practice? George D BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691 [No Abstract] [Full Text] [Related]